View Future GrowthFidia 과거 순이익 실적과거 기준 점검 0/6Fidia 의 수입은 연평균 -12.6%의 비율로 감소해 온 반면, Machinery 산업은 연평균 8.2%의 비율로 증가했습니다. 매출은 연평균 6.5%의 비율로 감소해 왔습니다.핵심 정보-12.57%순이익 성장률28.91%주당순이익(EPS) 성장률Machinery 산업 성장률19.41%매출 성장률-6.48%자기자본이익률-58.49%순이익률-10.37%최근 순이익 업데이트30 Jun 2025최근 과거 실적 업데이트Reported Earnings • Oct 25First half 2024 earnings released: €0.21 loss per share (vs €0.30 loss in 1H 2023)First half 2024 results: €0.21 loss per share. Revenue: €9.42m (up 4.8% from 1H 2023). Net loss: €7.22m (loss widened 246% from 1H 2023).Reported Earnings • Jun 09Full year 2023 earnings released: €0.19 loss per share (vs €0.86 profit in FY 2022)Full year 2023 results: €0.19 loss per share (down from €0.86 profit in FY 2022). Revenue: €29.9m (up 21% from FY 2022). Net loss: €1.31m (down 122% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 18First half earnings releasedOver the last 12 months the company has reported total losses of €3.72m, with losses widening by 47% from the prior year. Total revenue was €38.1m over the last 12 months, down 31% from the prior year.공시 • Sep 05Fidia S.p.A. to Report First Half, 2020 Results on Sep 11, 2020Fidia S.p.A. announced that they will report first half, 2020 results on Sep 11, 2020모든 업데이트 보기Recent updates공시 • 11hFidia S.p.A., Annual General Meeting, Jun 29, 2026Fidia S.p.A., Annual General Meeting, Jun 29, 2026, at 10:00 W. Europe Standard Time.New Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (446% increase in shares outstanding). Market cap is less than US$10m (€189.8k market cap, or US$223.4k). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).분석 기사 • Sep 26The Market Doesn't Like What It Sees From Fidia S.p.A.'s (BIT:FDA) Revenues Yet As Shares Tumble 27%Unfortunately for some shareholders, the Fidia S.p.A. ( BIT:FDA ) share price has dived 27% in the last thirty days...분석 기사 • Aug 01Why Investors Shouldn't Be Surprised By Fidia S.p.A.'s (BIT:FDA) 34% Share Price PlungeFidia S.p.A. ( BIT:FDA ) shares have had a horrible month, losing 34% after a relatively good period beforehand. For...분석 기사 • May 26Investors Aren't Buying Fidia S.p.A.'s (BIT:FDA) RevenuesFidia S.p.A.'s ( BIT:FDA ) price-to-sales (or "P/S") ratio of 0.2x may look like a pretty appealing investment...New Risk • May 23New major risk - Revenue and earnings growthEarnings have declined by 7.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.5m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 7.6% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 23x increase in shares outstanding). Market cap is less than US$10m (€3.88m market cap, or US$4.41m).New Risk • May 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Shareholders have been substantially diluted in the past year (over 23x increase in shares outstanding). Market cap is less than US$10m (€2.91m market cap, or US$3.25m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).New Risk • May 06New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 11x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (32% average weekly change). Shareholders have been substantially diluted in the past year (over 11x increase in shares outstanding). Market cap is less than US$10m (€1.44m market cap, or US$1.63m).Reported Earnings • Oct 25First half 2024 earnings released: €0.21 loss per share (vs €0.30 loss in 1H 2023)First half 2024 results: €0.21 loss per share. Revenue: €9.42m (up 4.8% from 1H 2023). Net loss: €7.22m (loss widened 246% from 1H 2023).분석 기사 • Oct 18Investors Give Fidia S.p.A. (BIT:FDA) Shares A 34% HidingTo the annoyance of some shareholders, Fidia S.p.A. ( BIT:FDA ) shares are down a considerable 34% in the last month...분석 기사 • Aug 29It's Down 40% But Fidia S.p.A. (BIT:FDA) Could Be Riskier Than It LooksUnfortunately for some shareholders, the Fidia S.p.A. ( BIT:FDA ) share price has dived 40% in the last thirty days...New Risk • Jul 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.17m (US$9.96m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.3m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (349% increase in shares outstanding). Market cap is less than US$10m (€9.17m market cap, or US$9.96m).분석 기사 • Jun 20Further Upside For Fidia S.p.A. (BIT:FDA) Shares Could Introduce Price Risks After 28% BounceFidia S.p.A. ( BIT:FDA ) shares have continued their recent momentum with a 28% gain in the last month alone. Still...Buy Or Sell Opportunity • Jun 16Now 20% undervaluedOver the last 90 days, the stock has risen 81% to €0.66. The fair value is estimated to be €0.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 9.8% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Jun 16Now 20% undervaluedOver the last 90 days, the stock has risen 81% to €0.66. The fair value is estimated to be €0.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 9.8% over the last 3 years. Meanwhile, the company became loss making.New Risk • Jun 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (349% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€19.8m market cap, or US$21.3m).Reported Earnings • Jun 09Full year 2023 earnings released: €0.19 loss per share (vs €0.86 profit in FY 2022)Full year 2023 results: €0.19 loss per share (down from €0.86 profit in FY 2022). Revenue: €29.9m (up 21% from FY 2022). Net loss: €1.31m (down 122% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.분석 기사 • May 28Estimating The Fair Value Of Fidia S.p.A. (BIT:FDA)Key Insights The projected fair value for Fidia is €0.84 based on 2 Stage Free Cash Flow to Equity Current share price...New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (349% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€15.8m market cap, or US$16.8m).New Risk • Apr 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 349% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (349% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€12.0m market cap, or US$12.8m).New Risk • Mar 31New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 37% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Market cap is less than US$10m (€3.10m market cap, or US$3.34m). Minor Risk Shareholders have been diluted in the past year (37% increase in shares outstanding).분석 기사 • Feb 13Risks Still Elevated At These Prices As Fidia S.p.A. (BIT:FDA) Shares Dive 31%Unfortunately for some shareholders, the Fidia S.p.A. ( BIT:FDA ) share price has dived 31% in the last thirty days...분석 기사 • Dec 23Is Fidia (BIT:FDA) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Oct 04Fidia S.p.A.'s (BIT:FDA) Business Is Trailing The Industry But Its Shares Aren'tThere wouldn't be many who think Fidia S.p.A.'s ( BIT:FDA ) price-to-sales (or "P/S") ratio of 0.3x is worth a mention...New Risk • Jun 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.6% operating cash flow to total debt). High level of non-cash earnings (96% accrual ratio). Market cap is less than US$10m (€9.01m market cap, or US$9.81m). Minor Risks Share price has been volatile over the past 3 months (5.0% average weekly change). Shareholders have been diluted in the past year (36% increase in shares outstanding).Board Change • Nov 16Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 3 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Chairman, CEO, President, MD & GM Giuseppe Morfino is the most experienced director on the board, commencing their role in 2002. Independent Director Laura Morgagni was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Board Change • Apr 27Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 3 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Chairman, CEO, President, MD & GM Giuseppe Morfino is the most experienced director on the board, commencing their role in 2002. Independent Director Laura Morgagni was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Is New 90 Day High Low • Feb 13New 90-day high: €2.74The company is up 6.0% from its price of €2.58 on 13 November 2020. The Italian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 15% over the same period.Is New 90 Day High Low • Dec 30New 90-day low: €1.43The company is down 42% from its price of €2.46 on 01 October 2020. The Italian market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 12% over the same period.Is New 90 Day High Low • Dec 07New 90-day low: €2.08The company is down 22% from its price of €2.67 on 08 September 2020. The Italian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 11% over the same period.Is New 90 Day High Low • Nov 20New 90-day low: €2.15The company is down 22% from its price of €2.77 on 21 August 2020. The Italian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 12% over the same period.Is New 90 Day High Low • Oct 14New 90-day low: €2.30The company is down 16% from its price of €2.73 on 16 July 2020. The Italian market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 19% over the same period.Major Estimate Revision • Oct 02Analysts lower revenue estimates to €26.0mThe 2020 consensus revenue estimate decreased from €33.0m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -€0.21 to -€0.98 for the same period. The Machinery industry in Italy is expected to see a 8.2% decline in net income next year. The consensus price target was lowered from €3.00 to €2.50. Share price is down by 1.2% to €2.43 over the past week.Is New 90 Day High Low • Sep 28New 90-day low: €2.40The company is down 16% from its price of €2.86 on 30 June 2020. The Italian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 12% over the same period.Reported Earnings • Sep 18First half earnings releasedOver the last 12 months the company has reported total losses of €3.72m, with losses widening by 47% from the prior year. Total revenue was €38.1m over the last 12 months, down 31% from the prior year.공시 • Sep 05Fidia S.p.A. to Report First Half, 2020 Results on Sep 11, 2020Fidia S.p.A. announced that they will report first half, 2020 results on Sep 11, 2020매출 및 비용 세부 내역Fidia가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BIT:FDA 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비30 Jun 2521-211031 Mar 2519-611031 Dec 2418-911030 Sep 2424-811030 Jun 2430-611031 Mar 2429-411031 Dec 2329-111030 Sep 2326-311030 Jun 2324-512031 Mar 2324111031 Dec 2225611031 Dec 2124-311031 Dec 2022-611030 Jun 2038-415031 Mar 2043-417031 Dec 1946-417030 Sep 1957-219030 Jun 1955-319031 Mar 1961-119031 Dec 1859-119030 Sep 1849-419030 Jun 1854-319031 Mar 1847-419031 Dec 1747-319030 Sep 1751-120030 Jun 1750-119031 Mar 1759119031 Dec 1659219030 Sep 1658219030 Jun 1659319031 Mar 1663419031 Dec 1561319030 Sep 1563518030 Jun 15655180양질의 수익: FDA 은(는) 현재 수익성이 없습니다.이익 마진 증가: FDA는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: FDA은 수익성이 없으며 지난 5년 동안 손실이 연평균 12.6% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 FDA의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: FDA은 수익성이 없어 지난 해 수익 성장률을 Machinery 업계(1.4%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: FDA는 현재 수익성이 없으므로 자본 수익률이 음수(-58.49%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YCapital-goods 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 08:06종가2026/05/22 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Fidia S.p.A.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Alberto FranceseIntesa Sanpaolo Equity ResearchSebastiano GrisettiIntesa Sanpaolo Equity Research
Reported Earnings • Oct 25First half 2024 earnings released: €0.21 loss per share (vs €0.30 loss in 1H 2023)First half 2024 results: €0.21 loss per share. Revenue: €9.42m (up 4.8% from 1H 2023). Net loss: €7.22m (loss widened 246% from 1H 2023).
Reported Earnings • Jun 09Full year 2023 earnings released: €0.19 loss per share (vs €0.86 profit in FY 2022)Full year 2023 results: €0.19 loss per share (down from €0.86 profit in FY 2022). Revenue: €29.9m (up 21% from FY 2022). Net loss: €1.31m (down 122% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 18First half earnings releasedOver the last 12 months the company has reported total losses of €3.72m, with losses widening by 47% from the prior year. Total revenue was €38.1m over the last 12 months, down 31% from the prior year.
공시 • Sep 05Fidia S.p.A. to Report First Half, 2020 Results on Sep 11, 2020Fidia S.p.A. announced that they will report first half, 2020 results on Sep 11, 2020
공시 • 11hFidia S.p.A., Annual General Meeting, Jun 29, 2026Fidia S.p.A., Annual General Meeting, Jun 29, 2026, at 10:00 W. Europe Standard Time.
New Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (446% increase in shares outstanding). Market cap is less than US$10m (€189.8k market cap, or US$223.4k). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
분석 기사 • Sep 26The Market Doesn't Like What It Sees From Fidia S.p.A.'s (BIT:FDA) Revenues Yet As Shares Tumble 27%Unfortunately for some shareholders, the Fidia S.p.A. ( BIT:FDA ) share price has dived 27% in the last thirty days...
분석 기사 • Aug 01Why Investors Shouldn't Be Surprised By Fidia S.p.A.'s (BIT:FDA) 34% Share Price PlungeFidia S.p.A. ( BIT:FDA ) shares have had a horrible month, losing 34% after a relatively good period beforehand. For...
분석 기사 • May 26Investors Aren't Buying Fidia S.p.A.'s (BIT:FDA) RevenuesFidia S.p.A.'s ( BIT:FDA ) price-to-sales (or "P/S") ratio of 0.2x may look like a pretty appealing investment...
New Risk • May 23New major risk - Revenue and earnings growthEarnings have declined by 7.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.5m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 7.6% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 23x increase in shares outstanding). Market cap is less than US$10m (€3.88m market cap, or US$4.41m).
New Risk • May 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Shareholders have been substantially diluted in the past year (over 23x increase in shares outstanding). Market cap is less than US$10m (€2.91m market cap, or US$3.25m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
New Risk • May 06New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 11x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (32% average weekly change). Shareholders have been substantially diluted in the past year (over 11x increase in shares outstanding). Market cap is less than US$10m (€1.44m market cap, or US$1.63m).
Reported Earnings • Oct 25First half 2024 earnings released: €0.21 loss per share (vs €0.30 loss in 1H 2023)First half 2024 results: €0.21 loss per share. Revenue: €9.42m (up 4.8% from 1H 2023). Net loss: €7.22m (loss widened 246% from 1H 2023).
분석 기사 • Oct 18Investors Give Fidia S.p.A. (BIT:FDA) Shares A 34% HidingTo the annoyance of some shareholders, Fidia S.p.A. ( BIT:FDA ) shares are down a considerable 34% in the last month...
분석 기사 • Aug 29It's Down 40% But Fidia S.p.A. (BIT:FDA) Could Be Riskier Than It LooksUnfortunately for some shareholders, the Fidia S.p.A. ( BIT:FDA ) share price has dived 40% in the last thirty days...
New Risk • Jul 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.17m (US$9.96m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.3m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (349% increase in shares outstanding). Market cap is less than US$10m (€9.17m market cap, or US$9.96m).
분석 기사 • Jun 20Further Upside For Fidia S.p.A. (BIT:FDA) Shares Could Introduce Price Risks After 28% BounceFidia S.p.A. ( BIT:FDA ) shares have continued their recent momentum with a 28% gain in the last month alone. Still...
Buy Or Sell Opportunity • Jun 16Now 20% undervaluedOver the last 90 days, the stock has risen 81% to €0.66. The fair value is estimated to be €0.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 9.8% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Jun 16Now 20% undervaluedOver the last 90 days, the stock has risen 81% to €0.66. The fair value is estimated to be €0.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 9.8% over the last 3 years. Meanwhile, the company became loss making.
New Risk • Jun 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (349% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€19.8m market cap, or US$21.3m).
Reported Earnings • Jun 09Full year 2023 earnings released: €0.19 loss per share (vs €0.86 profit in FY 2022)Full year 2023 results: €0.19 loss per share (down from €0.86 profit in FY 2022). Revenue: €29.9m (up 21% from FY 2022). Net loss: €1.31m (down 122% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
분석 기사 • May 28Estimating The Fair Value Of Fidia S.p.A. (BIT:FDA)Key Insights The projected fair value for Fidia is €0.84 based on 2 Stage Free Cash Flow to Equity Current share price...
New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (349% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€15.8m market cap, or US$16.8m).
New Risk • Apr 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 349% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (349% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€12.0m market cap, or US$12.8m).
New Risk • Mar 31New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 37% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Market cap is less than US$10m (€3.10m market cap, or US$3.34m). Minor Risk Shareholders have been diluted in the past year (37% increase in shares outstanding).
분석 기사 • Feb 13Risks Still Elevated At These Prices As Fidia S.p.A. (BIT:FDA) Shares Dive 31%Unfortunately for some shareholders, the Fidia S.p.A. ( BIT:FDA ) share price has dived 31% in the last thirty days...
분석 기사 • Dec 23Is Fidia (BIT:FDA) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • Oct 04Fidia S.p.A.'s (BIT:FDA) Business Is Trailing The Industry But Its Shares Aren'tThere wouldn't be many who think Fidia S.p.A.'s ( BIT:FDA ) price-to-sales (or "P/S") ratio of 0.3x is worth a mention...
New Risk • Jun 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.6% operating cash flow to total debt). High level of non-cash earnings (96% accrual ratio). Market cap is less than US$10m (€9.01m market cap, or US$9.81m). Minor Risks Share price has been volatile over the past 3 months (5.0% average weekly change). Shareholders have been diluted in the past year (36% increase in shares outstanding).
Board Change • Nov 16Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 3 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Chairman, CEO, President, MD & GM Giuseppe Morfino is the most experienced director on the board, commencing their role in 2002. Independent Director Laura Morgagni was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Board Change • Apr 27Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 3 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Chairman, CEO, President, MD & GM Giuseppe Morfino is the most experienced director on the board, commencing their role in 2002. Independent Director Laura Morgagni was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Is New 90 Day High Low • Feb 13New 90-day high: €2.74The company is up 6.0% from its price of €2.58 on 13 November 2020. The Italian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 15% over the same period.
Is New 90 Day High Low • Dec 30New 90-day low: €1.43The company is down 42% from its price of €2.46 on 01 October 2020. The Italian market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 12% over the same period.
Is New 90 Day High Low • Dec 07New 90-day low: €2.08The company is down 22% from its price of €2.67 on 08 September 2020. The Italian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 11% over the same period.
Is New 90 Day High Low • Nov 20New 90-day low: €2.15The company is down 22% from its price of €2.77 on 21 August 2020. The Italian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 12% over the same period.
Is New 90 Day High Low • Oct 14New 90-day low: €2.30The company is down 16% from its price of €2.73 on 16 July 2020. The Italian market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 19% over the same period.
Major Estimate Revision • Oct 02Analysts lower revenue estimates to €26.0mThe 2020 consensus revenue estimate decreased from €33.0m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -€0.21 to -€0.98 for the same period. The Machinery industry in Italy is expected to see a 8.2% decline in net income next year. The consensus price target was lowered from €3.00 to €2.50. Share price is down by 1.2% to €2.43 over the past week.
Is New 90 Day High Low • Sep 28New 90-day low: €2.40The company is down 16% from its price of €2.86 on 30 June 2020. The Italian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 12% over the same period.
Reported Earnings • Sep 18First half earnings releasedOver the last 12 months the company has reported total losses of €3.72m, with losses widening by 47% from the prior year. Total revenue was €38.1m over the last 12 months, down 31% from the prior year.
공시 • Sep 05Fidia S.p.A. to Report First Half, 2020 Results on Sep 11, 2020Fidia S.p.A. announced that they will report first half, 2020 results on Sep 11, 2020